Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

Creative Commons License

Yumuk P., Turhal N., Gumus M., Hatabay N., Turken O., Ozkan A., ...More

BMC CANCER, vol.5, 2005 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2005
  • Doi Number: 10.1186/1471-2407-5-10
  • Title of Journal : BMC CANCER


Background: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lung cancer (NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We retrospectively reviewed the data of 51 consecutive patients receiving C and day 1 and 8 P chemotherapy (CT) regimen in advanced stage NSCLC to evaluate the efficacy and toxicity.